Defining Tumor-associated Glycans as Molecular Drivers of Malignancy and Therapeutic Resistance in ErbB2-Positive Advanced Gastric Cancer

Advanced gastric and gastroesophageal cancer (GC) remains a worldwide health concern characterized by poor patient prognosis, mainly due to late disease diagnosis and lack of efficient therapeutic strategies. Efforts towards the comprehensive molecular profiling of tumors have revealed potential therapeutic targets, one of which is the ErbB2 receptor. ErbB2 is overexpressed in 10-20% GC cases, making patients eligible to undergo therapy with the ErbB2-specific trastuzumab (TTZ) monoclonal ant...